birth defects

The company's new clinical laboratory will provide interim and backup services for its customers.

The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.

The four-year project aims to sequence about 800 kids and their parents to get a clearer idea of the genetic underpinnings of birth defects with unknown causes. 

The Suzhou, China-based laboratory will focus on neonatal testing and infectious diseases, with the potential to expand into cancer testing. 

NEW YORK (GenomeWeb News) – Researchers from Stephen Quake's laboratory at Stanford University have a published a method in Nature describing a way to noninvasively sequence a fetal genome and identify clinically relevant alleles without prior knowledge of paternal genetic data.

A new, $4 million per-year grant program will fund basic and translational studies of the genetic and molecular basis of congenital birth defects.

Quest, whose ClariSure test is based on a bacterial artificial chromosome array, is also considering adopting oligonucleotide array-based platforms sold by companies such as Affymetrix, Agilent Technologies, Illumina, and others.

BioArray Briefs

Premium

Quest Diagnostics, Centre for Proteomic and Genomic Research, SimuGen, Arrayit, Phalanx, Rosetta Biosoftware, Exiqon, Norgen Biotek, TcLand Expression, Genedata, GeneGo, Entelos, Integrated DNA Technologies, VH Bio, SciGene, Inter Medico

Pages

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.